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What does this work add to what is already known? 
The QUiPP v.2 app is a reliable risk assessment tool that combines risk factors with fetal 
fibronectin and cervical length and calculates a simple % risk of spontaneous preterm birth.   
What are the clinical implications of this work? 
Use of QUiPP should increase confidence in clinical decisions, improve targeting and timing of 
interventions to reduce preterm birth and its associated morbidities, and limit unnecessary 
intervention and women’s anxiety. 




To develop enhanced prediction models to update the QUiPP app, a tool for predicting 
spontaneous preterm birth in women with symptoms of threatened preterm labour (TPTL), 
incorporating risk factors, transvaginal ultrasound assessment of cervical length (CL, mm) and 
cervicovaginal fluid quantitative fetal fibronectin test results (qfFN). 
Methods 
Participants were pregnant women between 23+0 and 34+6 weeks’ gestation with symptoms of 
TPTL, recruited as part of four prospective cohort studies carried out at 16 UK hospitals between 
October 2010 and October 2017.  The training set comprised all women where outcomes were 
known at May 2017 (n=1032). The validation set comprised women where outcomes were 
gathered between June 2017 and March 2018 (n=506).  Parametric survival models were 
developed for three combinations of predictors: risk factors plus qfFN test, risk factors plus CL 
only, and risk factors plus both tests.  The best models were selected using the Akaike and 
Bayesian information criteria.  The estimated probability of delivery before 30, 34 or 37 weeks’ 
gestation and within 1 or 2 weeks of testing was calculated and Receiver Operating 
Characteristic (ROC) curves were created to demonstrate the diagnostic ability of the prediction 
models.  
Results 
Predictive statistics were similar in training and validation sets. Areas under the ROC curves 
(validation set) demonstrated good prediction at all time points, particularly in the combination 
of risk factors plus qfFN model: 0.96 (<30 weeks); 0.85 (<34 weeks); 0.77 (<37 weeks); 0.91 (<1 
week) and 0.92 (<2 weeks). 
Conclusions 
Validation of these prediction models suggests the QUiPP v.2 app can reliably calculate risk of 
preterm delivery in women with TPTL.  Use of the QUiPP app in practice could lead to better 
targeting of intervention, while providing reassurance and avoiding unnecessary intervention 
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INTRODUCTION 
 
Although advances in care have led to more, and earlier, babies surviving, preterm birth remains 
hard to predict, even in women with symptoms of threatened preterm labour (TPTL).  
Symptoms of TPTL are not accurate predictors of preterm birth1,2 but because the consequences 
of not treating women in “true” preterm labour could be devastating, many receive 
unnecessary interventions.  Overtreatment results in avoidable exposure to the danger of 
adverse effects, particularly with repeated doses of steroids for fetal lung maturation, as this 
has been associated with reduced birth weight3-5. It also results in significant unnecessary 
healthcare expenditure6-8.   
 
In the absence of definitive diagnostic tests for early labour, management decisions are based 
on assessment of risk.  Risk assessment in TPTL is difficult, however, due to its multifactorial 
nature.  Risk factors, such as previous spontaneous preterm birth (sPTB) and cervical surgery, 
along with gestation and nature of symptoms, need to be considered.  Additional tests, e.g. 
transvaginal ultrasound cervical length measurement (TVS CL) and fetal fibronectin (fFN) can 
aid clinical decision making9-13. The potential of fFN as a predictive marker for sPTB has been 
established for several years14-19.  In the UK, test results were, until relatively recently, 
presented as dichotomous (i.e. positive or negative), based on a threshold of 50 ng/ml.  Newer 
fFN analysers provide results as concentrations in ng/ml, and it has been suggested that using 
alternative thresholds, i.e. <10 ng/ml and >200 ng/ml, rather than 50 ng/ml, may improve 
positive prediction14,20. 
 
We developed the QUiPP mobile phone application (www.quipp.org) for clinical decision 
support in women at increased risk of sPTB.  This easy-to-use risk assessment tool combines 
risk factors and test results, and calculates a simple % risk for individual women.  Algorithms 
used in generating the risk prediction scores for the first version of QUiPP have been previously 
reported21,22.  This paper reports further development and validation of algorithms for 
calculating risk in women with symptoms incorporated in the second version of the app. These 
new algorithms improve the utility and flexibility of QUiPP through the introduction of 
additional risk factors and calculation of risk using either quantitative fFN (ng/ml), TVS CL (mm) 
or both tests combined. 
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METHODS 
 
Upgrade of the QUiPP app was originally planned to include all PETRA study recruits, an 
observational study designed to collect data for this purpose (REC reference 14/LO/1988).  
However, before the participant recruitment phase was complete, a funding application to 
evaluate the QUiPP app’s usability, acceptability and effect on management, in a clinical trial, 
was successful (EQUIPTT, REC Ref. 17/LO/1802; ISRCTN trial registry number ISRCTN17846337).   
A decision was taken to update the predictive algorithms prior to completion of PETRA using all 
outcome data already gathered (at the end of May 2017) along with relevant participant data, 
i.e. matched eligibility criteria and symptoms of TPTL, from earlier prospective cohort studies 
[EQUIPP (REC Ref. 10/H0806/68), POPPY (REC Ref. 09/H0802/97) and INSIGHT (REC Ref. 
13/LO/0393)].  These studies all investigated preterm birth prediction and, like PETRA, utilised 
our Preterm Birth Studies database (www.medscinet.net/ptbstudies). A summary of study 
characteristics and number of participants from each study included in the training set is shown 
in Figure 1. 
 
Participants were pregnant women between 23+0 and 34+6 weeks gestation with symptoms of 
threatened preterm labour (e.g. abdominal pain or tightenings).  Women were excluded if 
diagnosed with established labour, ruptured membranes or antepartum haemorrhage.  Fetal 
fibronectin test results and cervical length measurements were known to attending clinicians 
and management, e.g. hospital admission, administration of steroids and tocolytics, was 
according to local protocols.  All data was gathered between October 2010 and October 2017 
from 16 UK hospitals.  
 
The training set for this analysis (n=1032) included data from 382 EQUIPP study participants 
(37%) that had been used for development of the first QUiPP symptomatic algorithms21, 
although this was limited to data relating to women with only fFN test results and singleton 
pregnancies.  As there was no statistical reason to exclude these data from the current analysis, 
they were incorporated in order to increase the predictive ability of the new models.  Additional 
data on cervical length and twin pregnancies, collected since creation of the first prediction 
models, increases the flexibility of the QUiPP app in practice. The new models were tested by 
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calibration before being applied in the second version of the QUiPP app. CE Marking as a Class 
1 Medical Device was granted before general release in September 2017. (MHRA Ref. no. for 
Medical Device/standalone software Z301 registration is A015030).  Formal validation of the 
prediction models was carried out after completion of the PETRA study (April 2018, n=506).   
 
Power calculation 
A power calculation was performed prior to commencement of the PETRA study. We 
anticipated that clinicians would be willing to view women in the lower risk group as closer to 
the normal (i.e. standard risk) if the true rate of PTL in this group could be demonstrated (with 
95% confidence) to be lower than the expected rate for women with TPTL symptoms (i.e. lower 
than 10% with a best estimate of 6.7%),  and concluded that full data on 550 standard risk 
women and 61 high risk women (total 611 women) in the proposed validation would be 
sufficient to achieve 80% power in the PETRA study. Allowing for 95% compliance & completion, 
a recruitment target of 643 women was considered adequate to validate the predictive value 
of each test (qfFN and CL) with an additional 300 to be used as a training set.  The final numbers 
used in the development and validation of the new algorithms provide sufficient power to 
achieve our objectives.  
 
Predictive model generation 
 
In total, six prediction algorithms were needed for the development of the new version (v.2) of 
the QUiPP app: three for symptomatic women, three for asymptomatic women. The algorithm 
is selected according to whether the woman is asymptomatic high risk (e.g. with a previous 
history of preterm birth, preterm prelabour ruptured membranes, late miscarriage or cervical 
surgery) or symptomatic of TPTL (any risk status) and whether her risk assessment includes qfFN 
concentration alone, CL measurement alone, or both test results.  Data were therefore split and 
tested in six groups: asymptomatic high risk with: i) qfFN test; ii) CL measurement; iii) both test 
results; and symptomatic (any risk status) with iv) qfFN test; v) CL measurement; vi) both test 
results.   In this paper, we report findings from the validation of the three algorithms 
appropriate for the cohorts symptomatic of TPTL. Development of the prediction models for 
asymptomatic high risk women are reported in our complementary paper (submitted to this 
journal on ##/04/2019). 
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Statistical analysis was carried out using Stata SE software (version 14.2; StataCorp, College 
Station, Texas, USA).  Exclusions were made for: incomplete data; invalid visits (out of gestation 
range, inappropriate symptoms, invalid or missing test results, sexual intercourse within 24 
hours) and major fetal abnormality (Figure 2).  Women with twin pregnancies were included, 
using the first twin gestation at delivery, but triplets and higher order multiples were excluded 
due to inadequate numbers.    Women whose labour was induced or who had caesarean section 
following preterm prelabour rupture of membranes (PPROM) were regarded as having had 
spontaneous preterm birth.  In multiple pregnancies, outcomes for the first baby were used in 
the analysis.    
 
Women who had received interventions that are intended to reduce the risk of sPTB (i.e. 
tocolysis, progesterone, cerclage and Arabin pessary) were not excluded in the models.  This is 
justified because, as this was not a randomised trial, any estimated treatment differences were 
likely to have been misleading, and could even have been in the wrong direction when 
compared to the true treatment effect.  A treatment paradox operates: typically the more 
severe the illness, the more likely that a clinical decision will be made to use a particular 
treatment.  A decision to treat to prevent early delivery is therefore a marker for greater risk of 
early delivery, even if the treatment itself tends to lengthen gestation.    Looking solely at 
untreated women would mean selecting the women perceived as at lowest risk, and so 
underestimating the risk of prematurity.  Including all women, irrespective of treatment, while 
not ideal, gives us the best estimate of risk in the clinical setting where the data was gathered.  
Additionally, if we include the changes associated with treatment in the app, there would be a 
real risk of clinicians using it to decide not to treat, even when treatment would be beneficial.  
 
Cox’s proportional hazards regression was used to determine which predictive risk factors to 
use in the model.  Factors tested included demographic characteristics, i.e. age, Body Mass 
Index (BMI, kg/m2), ethnicity, deprivation score and smoking), clinical risk factors (i.e. previous 
history of preterm birth or PPROM, late miscarriage, cervical surgery, twin pregnancy) and test 
results (qfFN and TVS CL).   Simple regression methods were not sophisticated enough for 
creation of the QUiPP app prediction models because time to delivery after testing has to be 
very precise, with very smooth survival curves, and therefore parametric survival analysis was 
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used.  This process involved testing the data using several different parametric survival analysis 
functions, namely exponential, gamma, Gompertz, log-logistic, log-normal and Weibull.     
Where women presented more than once in a pregnancy for TPTL assessment, later results 
were introduced as time-updated covariates, i.e. if delivery has not occurred before the next 
visit, prediction was recalculated with the next visit gestation.   In survival analysis, data are 
“censored” if the outcome of interest has not occurred during the follow up period23.  In this 
study, the data were censored, if spontaneous preterm birth had not occurred by 37 weeks’ 
gestation.   Iatrogenic preterm birth was treated as a non-event so data relating to women with 
this pregnancy outcome were censored at term.  Checks were undertaken to determine 
whether the data needed to be transformed before analysis using fractional polynomials.  The 
entire procedure was repeated for each of the three combinations of predictors (i.e. risk factors 
plus qfFN test, risk factors plus CL only, and risk factors plus both tests), and different models 
were produced in each case.  The best models were then determined by reference to Akaike’s 
Information Criterion (AIC) and Bayesian Information Criterion (BIC), where the lowest values 
are considered to have the best fit to the data24.  This is a method developed for comparing 
non-nested regression models where significance tests are not available. 
 
None of the predetermined demographic factors, i.e. age, BMI, ethnicity, deprivation score and 
smoking, affected prediction of sPTB in the models.  This was not because they have no value 
as predictors in themselves, but that the other predictors (i.e. major risk factors, qfFN and CL) 
were much stronger, so adding them did not affect the overall score. In testing the model with 
the cohort of women who had both fFN and CL test results, multivariate regression showed that 
only previous cervical surgery provided additional predictive power to fFN and CL test results in 
women with symptoms of TPTL.   However, the composite of risk factors used in the 
asymptomatic prediction algorithm for the QUiPP v.2 app, which was being developed in 
tandem, (i.e. multiple pregnancy, history of sPTB or PPROM, late miscarriage or cervical surgery) 
was tested to establish whether it affected the prediction in the symptomatic women.  There 
was little difference, so a decision was made to use this composite of risk factors for 
consistency. 
The prediction models were then tested by simple calibration. This meant comparing individual 
tests of clinically significant groups to confirm the actual event rates were consistent with the 
predicted probability of the event.  A 5% prediction rate for sPTB within 7 days of testing was 
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used as the threshold because this was the lowest value of a range of 5-15% that our TPTL 
Delphi consensus survey suggested should be recommended for intervention25.  The calibration 
tests provided reassurance that the models were acceptable to proceed with development of 
the QUiPP app before formal validation was undertaken. 
 
Predictive model validation 
Validation was carried out on a later subset of women from the PETRA study (n=506).  Predictive 
statistics, including sensitivity, specificity, balanced accuracy [(sens.+spec.)/2], likelihood ratios, 
positive (PPV) and negative predictive values (NPV) and separation probabilities (PPV+NPV-
100%) were calculated using a % risk of ≥5% as an indication of a positive test. This threshold 
was chosen, as it was for the calibration exercise, with reference to our TPTL Delphi consensus 
survey25. Results are tabulated with statistics for both the training and validation sets, by test 
group (risk factors plus either qfFN, CL or both tests) for prediction of spontaneous preterm 
birth at less than 30, 34 and 37 weeks’ gestation, and within 1 and 2 weeks post-test.  These 
time points were chosen because: i) the gestations at delivery are clinically important indicators 
for likely neonatal morbidity and ii) they are useful in guiding appropriate management, such 
as the timing of steroids.  Receiver operating characteristic (ROC) curves were drawn and areas 
under the curve (AUC) were calculated.   
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RESULTS 
Participant characteristics 
As explained above, three algorithms were developed so that the QUiPP app could be used in 
different symptomatic TPTL scenarios, i.e. when a women has: i) fFN testing alone, ii) CL 
measurement alone, or iii) both tests.  After exclusions, as shown in Figure 2, the training 
dataset comprised 1173 observations from 1032 women with fFN test results, and 229 
observations from 204 women with both qfFN and CL.   The validation set comprised 
observations involving 576 qfFN tests, (506 women), 155 CL measurements (132 women) and 
143 observations that include both qfFN and CL measurements (128 women).  The training 
set included 41 sets of twins, while the validation set included 32 sets.  Participant 
demographic characteristics and risk status by training and validation sets are shown in Tables 
1 and 2. 
 
Where intervention status was known, 30.3% (310/1024) women received steroids for fetal 
lung maturation, 8.2% (115/1405) received tocolysis.  Most women (92.4%, 1292/1399) 
received no prophylactic intervention for preterm birth risk (e.g. cerclage or progesterone). 
 
The prevalence of outcomes of sPTB at 30, 34 and 37 weeks’ gestation, and at or less than 1 
and 2 weeks of test for each of the test groups and between training and validation sets, were 
similar, as shown in Table 3. 
 
Predictive statistics 
The prediction models created generated formulae that provide individual risk scores 
dependent on risk factors and test results.  Tables 4, 5 and 6 show predictive statistics when 
the algorithms are tested on both the training and validation sets, by test group for prediction 
of sPTB at less than 30, 34 and 37 weeks’ gestation, and within 1 and 2 weeks post-test. 
 
Tables 4, 5 and 6 show a reasonable similarity between the training and validation sets at 
most outcome time points and for each combination of predictors.  In the qfFN group (the 
largest group), the ability of the algorithm to predict sPTB at less than 30 weeks’ gestation 
had the highest balanced accuracy with, in the validation set, a sensitivity of 90.0%, specificity 
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of 90.8%, a positive likelihood ratio (LR+) of 9.83, a negative likelihood ratio (LR-) of 0.11, 
positive predictive value (PPV) of 27.3% and a negative predictive value (NPV) of 99.6%.   
Although NPV will always be high where prevalence is low, when NPV is greater than the 
overall proportion of women unaffected, as it is with all combinations of predictors for sPTB 
<30 weeks’ (risk factors plus: qfFN 99.6% vs 96.3%; CL 98.1% vs 90.2%; both tests 100% vs 
90.4%), these findings demonstrate the usefulness of QUiPP as a predictive test.  
 
While the balanced accuracy statistics noted in Tables 4, 5 and 6 reflect the balance of 
sensitivity and specificity using the ≥5% risk cut off, the ROC curves shown in Figures 3, 4 and 
5 indicate overall test performance, using validation set only, at all percentage risks (i.e. 
without using ≥5% as a cut off for positive test).  The Area under the ROC curve (AUC) is a 
measure of how well the parameter (% risk) can distinguish between two groups, in this case, 
women with or without a pregnancy outcome of sPTB. 
 
For the qfFN group, the AUC for predicting sPTB at less than 30 weeks’ indicates good 
prediction, at 0.96, with similarly large AUCs for predicting sPTB at less than 1 week and 2 
weeks post test.  The risk prediction algorithm using cervical length appears to perform best 
at prediction of sPTB < 30 weeks, but this is inferior to the qfFN test.   When both test results 
are combined, the prediction improves, but is inferior to qfFN alone at all time points.   
 
In order to directly compare predictive ability of the different combinations of predictors we 
compared AUCs in the validation set of women who had had both tests (Figure 6 and Table 
7).   
 
Although the addition of CL to qfFN appears to be useful, the comparisons as shown in Table 
7, indicate there is no difference between the individual tests or combination of both tests 
for predicting sPTB at 30, 34 or 37 weeks.  However, at 1 and 2 weeks post test, qfFN alone 
appears to be a better predictor than CL alone, but it was no better than combined qfFN and 
CL.  CL alone, however, has reduced ability to predict sPTB, with AUCs of 0.6975 and 0.7306, 
respectively.   The number of women in this cohort having both tests was small (particularly 
so for prediction of sPTB at less than 30 weeks) so these results must be interpreted with 
caution.   
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As model development included data from women with interventions for reducing likelihood 
of sPTB (i.e. tocolysis, progesterone, cerclage and Arabin pessary), we wanted to confirm risk 
was not underestimated.  Consequently, we compared the models between women who had 
these interventions with those who had not.  We found the app either performed similarly in 
women with intervention (compared to those without) or showed significantly poorer 
agreement (i.e. smaller AUC) or higher risk (OR > 1 by logistic regression).   
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DISCUSSION 
 
In this study, we have demonstrated an improved ability of QUiPP algorithms to predict sPTB 
compared to those algorithms created for the first version of the app21.  The previous version 
included data from 382 women (190 training set, 192 validation set) with only the 
combination of risk factors and qfFN test results, as TVS CL data was unavailable.  Predictive 
statistics demonstrated the ability of the model to predict sPTB at <30, <34 and <37 weeks, 
and within 2 and 4 weeks, using a threshold of >10% as a positive result.   Using new 
algorithms created for QUiPP v.2, prediction was investigated for sPTB at <30, <34 and <37 
weeks, and within 1 and 2 weeks, using a threshold of ≥5%, with a substantially larger cohort 
(1032 training set and 506 validation set).  Although comparison can only be made with the 
qfFN group predictive statistics, our findings demonstrate a significant increase in sensitivity, 
the test’s ability to correctly predict sPTB, at all outcome time points.  Positive predictive 
values (PPV), i.e. probability that a woman with a positive test (in this case, a ≥ 5 or 10% risk 
of sPTB) will have sPTB, are lower in the later cohort while the negative predictive values 
(NPV), i.e. probability that a woman with a negative test (% risk < 5% or 10%) will not have 
sPTB, is similar to the Kuhrt21 cohort.  Unlike sensitivity and specificity, PPV and NPV are 
dependent on prevalence, and NPV will always be high where the prevalence is low.  In Kuhrt’s 
study, prevalence of sPTB was higher at all time points, so it is not surprising the PPV is higher 
than in the validation set.    
 
The AUCs demonstrating the predictive ability of QUiPP v.2 algorithms can also be compared 
with our previous findings21.  In this earlier study, we found AUCs of 0.88, 0.83, 0.77, 0.77 and 
0.78, for prediction of sPTB at <30, <34, <37 week’s gestation and within two and four weeks 
of testing, respectively.  This represented an overall improvement compared to an earlier 
systematic review of fFN for predicting sPTB 15.  Honest et al.’s review included data from 
forty studies and 26,876 women, in which ROC curves ranging from 0.71 to 0.77 
demonstrated the ability of fFN to predict sPTB at < 34 and <37 weeks’ respectively.    In the 
QUiPP v.2 validation set, AUCs were higher than previously reported15,21 in all but the <37 
weeks’ time point: 0.96 (<30 weeks); 0.85 (<34 weeks); 0.77 (<37 weeks); 0.91 (<1 week) and 
0.92 (<2 weeks).    
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Comparison of predictive statistics with our earlier work21 demonstrate improved prediction 
but are based on algorithms developed using risk factors and qfFN only.  QUiPP v.2 algorithms 
were created and validated for predicting sPTB using risk factors in combination with either 
qfFN, TVS CL or both tests.  The ability of QUiPP v.2 to predict sPTB using risk factors and 
either, or both tests, increases its utility and flexibility as it can be used where fFN testing is 
unavailable, and TVS CL is increasingly common as training becomes more widespread.   
 
When we compared the models between women who had interventions to reduce risk of 
sPTB with those who had not we found little difference, or reduced AUCs in the higher risk 
group receiving interventions.  This reduction in AUC is typically found when comparing 




Similar to other studies of TPTL, prevalence of preterm birth was low. Only 17 women (1.6%) 
of the total PETRA cohort (n=1037) delivered < 30 weeks’ gestation.  One reason for the low 
prevalence was because the prospective design meant women had to be recruited before the 
outcome (gestation at delivery) was known.  Many women whose TPTL symptoms progressed 
quickly into established labour could have been missed because research staff were unable 
to approach them before they delivered.  Despite the low prevalence, however, the overall 
cohort size is larger than previously reported, so the number of events is greater, which allows 
for increased confidence in the findings.   
 
Implications for practice 
 
The UK’s National Institute for Health and Care Excellence (NICE) Preterm Birth guideline26 
recommends that, in women over 30 weeks’ gestation, TVS CL should be offered first, 
followed by fFN testing, only if TVS CL is unavailable.   Combining both tests is not 
recommended.  While some investigators have found added value in combining tests27-31, 
others have not32,33.  In this project, the effect of combining CL with qfFN on predictive ability 
was also examined.  Results indicated prediction was not improved and, indeed, that TVS CL 
alone was inferior in predicting sPTB within 1 or 2 weeks (AUC 0.698 vs 0.875, sPTB < 1 week, 
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p=0.01; AUC 0.731 vs 0.889, sPTB < 2 weeks, p=0.02).  This suggests fFN has superior 
predictive ability, and based on these findings, fFN should be recommended as first choice of 
test in TPTL over TVS CL.  
For women with suspected PTL under 30 weeks’ gestation, NICE recommends a “treat all” 
strategy, without reference to either fFN or CL tests.  We modelled the effect of this strategy 
on a cohort of 188 symptomatic women < 30 weeks’, using the QUiPP app, and found that 
89% (n=169) of hospital admissions could have been safely avoided if a threshold of 5% risk 
of delivery within the seven days had been used to guide clinical practice34. 
 
In conclusion, QUiPP v.2 is a reliable, simple-to-use tool, which combines risk factors and test 
results into one simple % risk score. Its use could increase confidence in management 
decisions and lead to improved targeting and timing of interventions for reducing sPTB and 
its associated morbidities, while limiting unnecessary intervention and women’s anxiety. The 
ability of the new algorithms to predict sPTB < 30 weeks are particularly important and should 
inform revision of the current NICE “treat all” < 30 weeks strategy.  Results of the EQUIPTT 
trial35 may also provide evidence for review of the NICE recommendations.   
  
This article is protected by copyright. All rights reserved.
ACKNOWLEDGEMENTS 
 
The authors wish to thank all the women who took part in this study and Tommy’s charity 
which supports all the research in the Department of Women and Children’s Health at St 
Thomas’ Hospital.   This is a summary of independent research funded by the National 
Institute for Health Research (NIHR)’s NIHR/HEE CAT Clinical Doctoral Research Fellowship 
Programme (Ref.CDRF-2013-04-026). Paul Seed is partly funded by Tommy’s (Registered 
Charity No. 1060508) and by NIHR Collaboration for Leadership in Applied Health Research 
and Care, South London.  Jane Sandall is a National Institute for Health Research (NIHR) Senior 
Investigator and also supported by the NIHR Collaboration for Leadership in Applied Health 
Research and Care South London at King’s College Hospital NHS Foundation Trust.  The views 
expressed are those of the authors and not necessarily those of the NHS, the NIHR or the 
Department of Health and Social Care.   This research is supported by the NIHR BRC at Guy’s 
& St Thomas’ NHS Foundation Trust and King’s College, London, and at University College 
London Hospitals NHS Foundation Trust and University College London. 
This article is protected by copyright. All rights reserved.
REFERENCES 
1. Copper RL, Goldenberg RL, Davis RO, Cutter GR, DuBard MB, Corliss DK, Andrews JB. 
Warning symptoms, uterine contractions, and cervical examination findings in 
women at risk of preterm delivery. Am J Obstet Gynecol. 1990; 162(3): 748-754. 
2. Iams JD, Newman RB, Thom EA, Goldenberg RL, Mueller-Heubach E, Moawad A, Sibai 
BM, Caritis SN, Miodovnik M, Paul RH. Frequency of uterine contractions and the risk 
of spontaneous preterm delivery. N Engl J Med. 2002; 346(4): 250-255. 
3. Asztalos E, Willan A, Murphy K, Matthews S, Ohlsson A, Saigal S, Armson A, Kelly E, 
Delisle M, Gafni A. Association between gestational age at birth, antenatal 
corticosteroids, and outcomes at 5 years: multiple courses of antenatal 
corticosteroids for preterm birth study at 5 years of age (MACS-5). BMC Pregnancy 
Childbirth. 2014; 14(1): 272. 
4. Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN, Matthews SG, 
Saigal S, Asztalos E, Ross S. Multiple courses of antenatal corticosteroids for preterm 
birth (MACS): a randomised controlled trial. Lancet. 2008; 372(9656): 2143-2151. 
5. Norberg H, Stålnacke J, Nordenström A, Norman M. Repeat Antenatal Steroid 
Exposure and Later Blood Pressure, Arterial Stiffness, and Metabolic Profile. J 
Pediatr. 2013; 163(3): 711-716. 
6. Lucovnik M, Chambliss LR, Garfield RE. 2013, "Costs of unnecessary admissions and 
treatments for “threatened preterm labor.” Am J Obstet Gynecol. 2013; 209(3): 
217.e1-217.e3. 
7. Mozurkewich EL, Naglie G, Krahn MD, Hayashi RH. Predicting preterm birth: a cost-
effectiveness analysis. Am J Obstet Gynecol. 2000; 182(6): 1589-1598. 
8. van Baaren G, Vis JY, Grobman WA, Bossuyt PM, Opmeer BC, Mol BW. Cost-
effectiveness analysis of cervical length measurement and fibronectin testing in 
women with threatened preterm labor. Am J Obstet Gynecol. 2013; 209(5): 436.e1-
436.e8. 
9. Fuchs IB, Henrich W, Osthues K, Dudenhausen JW. Sonographic cervical length in 
singleton pregnancies with intact membranes presenting with threatened preterm 
labor. Ultrasound Obstet Gynecol. 2004; 24(5): 554-557. 
10. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, Thom E, McNellis D, 
Copper RL, Johnson F. The length of the cervix and the risk of spontaneous 
premature delivery. N Engl J Med. 1996; 334(9): 567-573. 
11. Leitich H, Brunbauer M, Kaider A, Egarter C, Husslein P. Cervical length and dilatation 
of the internal cervical os detected by vaginal ultrasonography as markers for 
preterm delivery: A systematic review. Am J Obstet Gynecol. 1999; 181(6): 1465-
1472. 
This article is protected by copyright. All rights reserved.
12. Owen J, Iams JD, National Institute of Child Health and Human Development 
Maternal-Fetal Medicine Units Network. What we have learned about cervical 
ultrasound. Semin Perinatol. 2003; 27(3): 194-203. 
13. Sotiriadis A, Papatheodorou S, Kavvadias A, Makrydimas G. Transvaginal cervical 
length measurement for prediction of preterm birth in women with threatened 
preterm labor: a meta‐analysis. Ultrasound Obstet Gynecol. 2010; 35(1): 54-64. 
14. Abbott DS, Radford SK, Seed PT, Tribe RM, Shennan AH. Evaluation of a quantitative 
fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J 
Obstet Gynecol. 2013; 208(2): 122. e1-122. e6. 
15. Honest H, Bachmann LM, Coomarasamy A, Gupta JK, Kleijnen J, Khan KS. Accuracy of 
cervical transvaginal sonography in predicting preterm birth: a systematic review. 
Ultrasound Obstet Gynecol. 2002; 22(3): 305-322. 
16. Leitich H, Egarter C, Kaider A, Hohlagschwandtner M, Berghammer P, Husslein P. 
Cervicovaginal fetal fibronectin as a marker for preterm delivery: a meta-
analysis. Am J Obstet Gynecol. 1999; 180(5): 1169-1176. 
17. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN, Jones L, Deligdisgh 
L, Garite TJ. Fetal fibronectin in cervical and vaginal secretions as a predictor of 
preterm delivery. N Engl J Med. 1991; 325(10):669-674. 
18. Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME, Hakomori S. The 
oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. 
Unique structural requirement for the antigenic specificity provided by a 
glycosylhexapeptide.  J Biol Chem. 1988; 263(7):3314-3322. 
19. Peaceman AM, Andrews WW, Thorp JM, Cliver SP, Lukes A, Iams JD, Coultrip L, 
Eriksen N, Holbrook RH, Elliott J, Ingardia C, Pietrantoni M. Fetal fibronectin as a 
predictor of preterm birth in patients with symptoms: A multicenter trial. Am J 
Obstet Gynecol. 1997; 177(1):13-18. 
20. Foster C, Shennan AH. Fetal fibronectin as a biomarker of preterm labor: a review of 
the literature and advances in its clinical use. Biomark Med. 2014; 8(4): 471-484. 
21. Kuhrt K, Hezelgrave N, Foster C, Seed PT, Shennan AH. Development and validation 
of a tool incorporating quantitative fetal fibronectin to predict spontaneous preterm 
birth in symptomatic women. Ultrasound Obstet Gynecol. 2016; 47(2): 210-216. 
22. Kuhrt K, Smout E, Hezelgrave N, Seed PT, Carter J, Shennan AH. Development and 
validation of a tool incorporating cervical length and quantitative fetal fibronectin to 
predict spontaneous preterm birth in asymptomatic high-risk women. Ultrasound 
Obstet Gynecol. 2016; 47(1): 104-109. 
23. Kleinbaum DG, Klein M. Survival analysis (Vol. 3). New York: Springer; 2010. 
24. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to 
regression analysis based on fractional polynomials for modelling continuous 
variables. London: John Wiley & Sons; 2008. 
This article is protected by copyright. All rights reserved.
25. Carter J, Tribe R, Watson H, Shennan AH. Threatened preterm labour management: 
results of a Delphi consensus on best practice: PL 37. Br J Obstet Gynaecol. 2016 Apr 
1; 123:100-101. 
26. National Institute for Health and Care Excellence. Preterm labour and birth. NICE 
guideline (NG25). 2015. 
27. Bolt LA, Chandiramani M, De Greeff A, Seed PT, Kurtzman J, Shennan AH. The value 
of combined cervical length measurement and fetal fibronectin testing to predict 
spontaneous preterm birth in asymptomatic high-risk women.  J Matern Fetal 
Neonatal Med. 2011; 24(7): 928-932. 
28. Bruijn MM, Vis J, Wilms FF, Oudijk M, Kwee A, Porath MM, Oei G, Scheepers H, 
Spaanderman ME, Bloemenkamp K. Quantitative fetal fibronectin testing in 
combination with cervical length measurement in the prediction of spontaneous 
preterm delivery in symptomatic women. Br J Obstet Gynaecol. 2016; 123(12): 1965-
1971. 
29. DeFranco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm 
labor: is the combination of fetal fibronectin and cervical length in symptomatic 
patients a useful predictor of preterm birth? A systematic review. Am J Obstet 
Gynecol. 2013; 208(3): 233.e1-233.e6. 
30. Gomez R, Romero R, Medina L, Nien JK, Chaiworapongsa T, Carstens M, Gonzalez R, 
Espinoza J, Iams JD, Edwin S, Rojas I. Cervicovaginal fibronectin improves the 
prediction of preterm delivery based on sonographic cervical length in patients with 
preterm uterine contractions and intact membranes. Am J Obstet Gynecol. 2005; 
192(2): 350-359. 
31. Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal 
fibronectin affect management of women with threatened preterm labor? A 
randomized trial. Am J Obstet Gynecol. 2007; 197(4): 426.e1-426.e7. 
32. Levine LD, Downes KL, Romero JA, Pappas H, Elovitz MA. Quantitative fetal 
fibronectin and cervical length in symptomatic women: results from a prospective 
blinded cohort study. J Matern Fetal Neonatal Med. 2018 May 15: 1-9. 
33. Tsoi E, Akmal S, Geerts L, Jeffery B, Nicolaides K. Sonographic measurement of 
cervical length and fetal fibronectin testing in threatened preterm labor. Ultrasound 
Obstet Gynecol. 2006; 27(4):368-372. 
34. Watson HA, Carter J, Seed PT, Tribe RM, Shennan AH. The QUiPP App: a safe 
alternative to a treat-all strategy for threatened preterm labor. Ultrasound Obstet 
Gynecol. 2017; 50(3): 342-346. 
35. Watson HA, Carlisle N, Kuhrt K, Tribe RM, Carter J, Seed P, Shennan AH. EQUIPTT: 
The Evaluation of the QUiPP app for Triage and Transfer protocol for a cluster 
randomised trial to evaluate the impact of the QUiPP app on inappropriate 
management for threatened preterm labour. BMC Pregnancy Childbirth. 2019; 19(1): 
68. 
This article is protected by copyright. All rights reserved.
FIGURES 
 
Figure 1: Summary of study characteristics and number of participants from each study 
included in the training and validation sets. 
 
Figure 2: Flow chart showing participants after exclusions and split between training and 
validation sets. TPTL = threatened preterm labour, qfFN = quantitative fetal fibronectin, CL = 
cervical length 
 
Figure 3. ROC curves showing QUiPP app prediction of spontaneous preterm birth (sPTB) at 
less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of testing in the group of 
women with fetal fibronectin (qfFN) test results in the validation set. AUC=area under the 
ROC curve. 
 
Figure 4. ROC curves showing QUiPP app prediction of spontaneous preterm birth (sPTB) at 
less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of testing in the group of 
women with cervical length (CL) in the validation set. AUC=area under the ROC curve. 
 
Figure 5. ROC curves showing QUiPP app prediction of spontaneous preterm birth (sPTB) at 
less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of testing in the group of 
women with both fetal fibronectin (qfFN) and cervical length (CL) in the validation set. 
AUC=area under the ROC curve. 
 
Figure 6. ROC curves showing ability of QUiPP app to predict spontaneous preterm birth 
(sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of testing in the 
group of women with both fetal fibronectin (fFN) and cervical length (CL) in the validation set, 
based on qfFN alone, CL alone, or combination of both tests. AUC=area under the ROC curve. 
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Table 1. Demographic characteristics of women in the training and validation sets. 
 Training  





AGE                                                            n=                                            
n= 
1032 506 1538 
mean (SD) 29.9 (5.7) 29.8 (6.0) 29.9 (5.8) 
BMI (kg/m2)                                             n=                                                
n= 
1025 506 1531 
mean (SD) 26.1 (5.9) 26.0 (6.1) 26.1 (5.9) 
IMD deprivation score                            n=             
n= 
947 504 1451 
mean (SD) 31.3 (13.5) 30.2 (15.2) 30.1 (14.1) 
ETHNICITY                                                 n=                                                
n= 
1024 (%) 506 (%) 1530 (%) 
European 562 (54.9) 326 (64.4) 888 (58.0) 
African or Caribbean 70 (6.8) 33 (6.5) 103 (6.7) 
Asian (India/Pakistan/Bangladesh) 277 (27.1) 92 (18.2) 369 (24.1) 
Other (incl. Chinese) 115 (11.2) 55 (10.9) 170 (11.1) 
  
SD=standard deviation; BMI=Body Mass Index; IMD=Index of Multiple Deprivation. 
†Numbers in groups differ when data is missing. 
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Table 2. Major risk factors of women in training and validation sets. 
 Training set 
n=1032  
Validation set      




  n (%) n (%) n (%) 
Previous PTB < 37 weeks 158 (15.3) 83 (16.4) 241 (15.7) 
Previous PPROM < 37 weeks 74 (7.2) 34 (6.7) 108 (7.0) 
Previous late miscarriage  79 (7.7) 13 (2.6) 92 (6.0) 
Cervical surgery 65 (6.3) 26 (5.1) 91 (5.9) 
Twin pregnancy 41 (4.0) 33 (6.5) 74 (4.8) 
   
PTB=preterm birth; PPROM=prelabour preterm ruptured membranes. 
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Table 3. Number of tests in each of the test groups with outcomes by training and validation 
sets and spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and 
within 1 and 2 weeks of testing. 
 
qfFN group  
Training set Validation set 
sPTB Total n=sPTB (%)  95% CI Total n=sPTB (%) 95% CI 
<30wk* 574 22 (3.8) 2.4-5.7 272 10 (3.7) 1.8-6.7 
<34wk** 1066 60 (5.6) 4.3-7.2 520 26 (5.0) 3.3-7.2 
<37wk 1173 144 (12.3) 10.5-14.3 576 68 (11.8) 9.3-14.7 
<1wk 1173 15 (1.3) 0.7-2.1 576 13 (2.3) 1.2-3.8 
<2wk 1173 38 (3.2) 2.3-4.4 576 18 (3.1) 1.9-4.9 
CL group  
Training set Validation set 
sPTB Total n=sPTB (%) 95% CI Total n=sPTB (%) 95% CI 
<30wk* 147 17 (11.6) 6.9-17.9 92 9 (9.8) 4.6-17.8 
<34wk** 214 41 (19.2) 14.1-25.1 150 17 (11.3) 6.7-17.5 
<37wk 229 69 (30.1) 24.3-36.5 155 32 (20.6) 14.6-27.9 
<1wk 229 8 (3.5) 1.5-6.8 155 7 (4.5) 1.8-9.1 
<2wk 229 21 (9.2) 5.8-13.7 155 8 (5.2) 2.3-9.9 
Both qfFN and CL group  
Training set Validation set 
sPTB Total n=sPTB (%) 95% CI Total n=sPTB (%) 95% CI 
<30wk* 147 17 (11.6) 6.9-17.9 83  8 (9.6) 4.3-18.1 
<34wk** 214 41 (19.2) 14.1-25.1 138  16 (11.6) 6.8-18.1 
<37wk 229 69 (30.1) 24.3-36.5 143  31 (21.7) 15.2-29.3 
<1wk 229 8 (3.5) 1.5-6.8 143  7 (4.9) 2.0-9.8 
<2wk 229 21 (9.2) 5.8-13.7 143 8 (5.6) 2.4-10.7 
*some women were recruited after 30 weeks therefore not included here.  
**some women were recruited after 34 weeks therefore not included here. 
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Table 4. Predictive statistics for spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of 




sPTB at less than sPTB within 
Outcome 30 wk 95% CI  34 wk 95% CI  37 wk 95% CI  1 wk 95% CI  2 wk 95% CI  
Sensitivity % 
Training 81.8% (59.7-94.8%) 80.0% (67.7-89.2%) 82.6% (75.4-88.4%) 73.3% (44.9-92.2%) 81.6% (65.7-92.3%) 
Validation 90.0% (55.5-99.7%) 84.6% (65.1-95.6%) 80.9% (69.5-89.4%) 53.8% (25.1-80.8%) 83.3% (58.6-96.4%) 
Specificity % 
Training 92.9% (90.5-94.9%) 74.2% (71.3-76.8%) 62.7% (59.6-65.6%) 94.0% (92.4-95.3%) 86.6% (84.5-88.5%) 
Validation 90.8% (86.7-94.0%) 70.9% (66.6-74.8%) 56.9% (52.5-61.2%) 92.0% (89.5-94.1%) 84.2% (80.9-87.2%) 
Balanced accuracy ((Sens.+Spec)/2) 
Training 87.38% (76.66-93.58%) 77.08% (71.41-81.91%) 72.66% (68.98-76.05) 83.64% (68.78-92.23%) 84.09% (76.81-89.41%) 
Validation 90.42% (75.96-96.57%) 77.73% (69.54-84.22%) 68.89% (63.28-73.99%) 72.93% (56.27-84.94%) 83.78% (73.07-90.77%) 
Likelihood ratio - positive 
Training 11.58 (8.07-16.62) 3.10 (2.63-3.65) 2.21 (1.99-2.47) 12.13 (8.29-17.75) 6.09 (4.93-7.53) 
Validation 9.83 (6.37-15.16) 2.90 (2.34-3.60) 1.88 (1.61-2.19) 6.74 (3.79-11.98) 5.28 (3.99-7.00) 
Likelihood ratio - negative 
Training 0.20 (0.08-0.47) 0.27 (0.16-0.45) 0.28 (0.19-0.40) 0.28 (0.12-0.66) 0.21 (0.11-0.42) 
Validation 0.11 (0.02-0.71) 0.22 (0.09-0.54) 0.34 (0.20-0.55) 0.50 (0.28-0.90) 0.20 (0.07-0.56) 
Positive Predictive Value (%) 
Training 31.6% (19.9-45.2%) 15.6% (11.7-20.1%) 23.7% (20.0-27.6%) 13.6% (7.0-23.0%) 16.9% (11.8-23.2%) 
Validation 27.3% (13.3-45.5) 13.3% (8.5-19.4%) 20.1% (15.5-25.3%) 13.5% (5.6-25.8%) 14.6% (8.4-22.9%) 
Negative Predictive Value (%) 
Training 99.2% (98.0-99.8%) 98.4% (97.3-99.2%) 96.3% (94.5-97.6%) 99.6% (99.1-99.9%) 99.3% (98.5-99.7%) 
Validation 99.6% (97.7-100%) 98.9% (97.1-99.7%) 95.7% (92.8-97.7%) 98.9% (97.5-99.6%) 99.4% (98.2-99.9%) 
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Table 5. Predictive statistics for spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of 




sPTB at less than sPTB within 
Outcome 30 wk 95% CI  34 wk 95% CI  37 wk 95% CI  1 wk 95% CI  2 wk 95% CI  
Sensitivity % 
Training 94.1% (71.3-99.9) 92.7% (80.1-98.5%) 100% (94.8-100%) 87.5% (47.3-99.7%) 81.0% (58.1-94.6%) 
Validation 88.9% (51.8-99.7%) 100% (80.5-100%) 100% (89.1-100%) 57.1% (18.4-90.1%) 75.0% (34.9-96.8%) 
Specificity % 
Training 63.8% (55.0-72.1) 35.8% (28.7-43.5%) 8.1% (4.4-13.5%) 81.0% (75.2-85.9%) 66.8% (60.0-73.2%) 
Validation 61.4% (50.1-71.9%) 34.6% (26.6-43.3%) 5.7% (2.3-11.4%) 78.4% (70.9-84.7%) 63.3% (54.9-71.1%) 
Balanced accuracy ((Sens.+Spec)/2) 
Training 78.98% (69.94-85.86%) 64.26% (56.75-71.13%) 54.06% (47.19-60.78%) 84.25% (68.68-92.88%) 73.89% (63.78-81.97%) 
Validation 75.17% (60.75-85.55%) 67.29% (57.50-75.78%) 52.85% (43.43-62.06%) 67.76% (46.69-83.45%) 69.13% (51.77-82.37%) 
Likelihood ratio - positive 
Training 2.60 (2.01-3.37) 1.44 (1.25-1.66) 1.09 (1.04-1.14) 4.60 (3.16-6.72) 2.44 (1.84-3.24) 
Validation 2.31 (1.61-3.29) 1.53 (1.35-1.73) 1.06 (1.02-1.11) 2.64 (1.30-5.38) 2.04 (1.30-3.21) 
Likelihood ratio - negative 
Training 0.09 (0.01-0.62) 0.20 (0.07-0.62) 0.00 - 0.15 (0.02-0.97) 0.29 (0.12-0.69) 
Validation 0.18 (0.03-1.16) 0.00 - 0.00 - 0.55 (0.23-1.29) 0.40 (0.12-1.32) 
Positive Predictive Value (%) 
Training 25.4% (15.3-37.9%) 25.5% (18.7-33.3%) 31.9% (25.8-38.6%) 14.3% (5.9-27.2%) 19.8% (12.0-29.8%) 
Validation 20.0% (9.1-35.6%) 16.3% (9.8-24.9%) 21.6% (15.3-29.1%) 11.1% (3.1-26.1%) 10.0% (3.8-20.5%) 
Negative Predictive Value (%) 
Training 98.8% (93.5-100%) 95.4% (87.1-99.0%) 100% (75.3-100%) 99.4% (96.9-100%) 97.2% (93.0-99.2%) 
Validation 98.1% (89.7-100%) 100% (92.3-100%) 100% (59.0-100%) 97.5% (92.8-99.5%) 97.9% (92.6-99.7%) 
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Table 6. Predictive statistics for spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of 
testing in the group of women with both cervicovaginal fluid fetal fibronectin (qfFN) and transvaginal USS cervical length (CL) by training and 
validation sets. 
 
qfFN & CL 
group 
 
sPTB at less than sPTB within 
Outcome  30 wk 95% CI  34 wk 95% CI  37 wk 95% CI  1 wk 95% CI  2 wk 95% CI  
 Sensitivity % 
Training  100% (80.5-100%) 92.7% (80.1-98.5%) 94.2% (85.8-98.4%) 100% (63.1-100%) 90.5% (69.6-98.8%) 
Validation  100% (63.1-100%) 93.8% (69.8-99.8%) 100% (88.8-100%) 85.7% (42.1-99.6%) 100% (63.1-100%) 
 Specificity % 
Training  68.5% (59.7-76.3%) 44.5% (37.0-52.2%) 16.3% (10.9-22.9%) 78.7% (72.7-83.9%) 69.2% (62.5-75.4%) 
Validation  60.0% (48.0-71.1%) 39.3% (30.6-48.6%) 16.1% (9.8-24.2%) 75.7% (67.6-82.7%) 60.0% (51.2-68.3%) 
 Balanced Accuracy ((Sens.+Spec)/2) 
Training  84.23% (77.72-89.11%) 68.60% (61.40-74.99%) 55.23% (48.37-61.89%) 89.37% (83.77-91.19%) 79.85% (71.41-86.28%) 
Validation  80.00% (69.22-87.68%) 66.55% (55.66-75.91%) 58.04% (48.82-66.72%) 80.72% (63.55-90.96%) 80.00% (70.46-87.03%) 
 Likelihood ratio - positive 
Training  3.17 (2.46-4.08) 1.67 (1.43-1.96) 1.12 (1.03-1.23) 4.70 (3.65-6.06) 2.94 (2.30-3.76) 
Validation  2.50 (1.89-3.30) 1.55 (1.28-1.87) 1.19 (1.10-1.29) 3.53 (2.31-5.40) 2.50 (2.03-3.07) 
 Likelihood ratio - negative 
Training  0.00 - 0.16 (0.05-0.49) 0.36 (0.13-0.98) 0.00 - 0.14 (0.04-0.52) 
Validation  0.00 - 0.16 (0.02-1.07) 0.00 - 0.19 (0.03-1.16) 0.00 - 
 Positive Predictive Value (%) 
Training  29.3% (18.1-42.7%) 28.4% (20.9-36.8%) 32.7% (26.2-39.7%) 14.5% (6.5-26.7%) 22.9% (14.4-33.4%) 
Validation  21.1% (9.6-37.3%) 16.9% (9.8-26.3%) 24.8% (17.5-33.3%) 15.4% (5.9-30.5%) 12.9% (5.7-23.9%) 
 Negative Predictive Value (%) 
Training  100% (95.9-100%) 96.3% (89.4-99.2%) 86.7% (69.3-96.2%) 100% (97.9-100%) 98.6% (95.1-99.8%) 
Validation  100% (92.1-100%) 98.0% (89.1-99.9%) 100% (81.5-100%) 99.0% (94.8-100%) 100% (95.5-100%) 
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Table 7. Comparison of area under the ROC curve (AUC) between QUiPP, prediction of 
spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation, and at 1 and 2 
weeks post test, using fetal fibronectin (qfFN) test alone, cervical length (CL) alone, and both 
tests combined.   
 
AUC for prediction of sPTB < 30 weeks (n=83*) 
 AUC Std Err 95%CI Pr>chi2 ** 
Both qfFN & CL 0.953 0.028 (0.899-1.000) standard 
qfFN alone 0.907 0.038 (0.832-0.982) 0.14 
CL alone 0.848 0.079 (0.693-1.000) 0.17 
AUC for prediction of sPTB < 34 weeks (n=138*) 
 AUC Std Err 95%CI Pr>chi2 ** 
Both qfFN & CL 0.831 0.052 (0.729-0.933) standard 
qfFN alone 0.783 0.062 (0.662-0.905) 0.09 
CL alone 0.789 0.055 (0.683-0.896) 0.35 
AUC for prediction of sPTB < 37 weeks (n=143) 
 AUC Std Err 95%CI Pr>chi2** 
Both qfFN & CL 0.731 0.051 (0.630-0.831) standard 
qfFN alone 0.692 0.053 (0.589-0.796) 0.24 
CL alone 0.719 0.050 (0.619-0.819) 0.75 
AUC for prediction of sPTB < 1 week (n=143) 
 AUC Std Err 95%CI Pr>chi2** 
Both qfFN & CL 0.875 0.056 (0.766-0.984) standard 
qfFN alone 0.893 0.042 (0.811-0.975) 0.65 
CL alone 0.698 0.126 (0.450-0.945) 0.01 
AUC for prediction of sPTB < 2 weeks (n=143) 
 AUC Std Err 95%CI Pr>chi2** 
Both qfFN & CL 0.889 0.049 (0.793-0.985) standard 
qfFN alone 0.904 0.036 (0.833-0.975) 0.67 
CL alone 0.731 0.113 (0.510-0.951) 0.02 
*number of observations. Some women were recruited at later gestations. 
** Pr>chi2 test of significance 
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Total (n=1,538)
Training set   (n=1,032)
INSIGHT
Study design: Prospective cohort –
predictive biomarkers for PTB prediction.
Recruited: March 2014 to May 2017.
Sites: C.
Inclusion:  10+0 to 28+0 weeks gestation, 
+/-TPTL; qfFN and/or TVS CL, +/- PTB risk.
Exclusion: Fetal anomaly, PPROM, APH.
PETRA
Study design: Prospective cohort - development and validation 
of QUiPP v.2 symptomatic prediction models.
Recruited: March 2014 to Oct 2017.
Sites:  C, D, F, G, H, I, J, K, L, M, N.
Inclusion:  23+0 to 34+6 weeks gestation, TPTL symptoms; qfFN 
and/or TVS CL, +/- PTB risk.
Exclusion: established labour, PPROM, APH.
Validation set (n=506)
Validation set (n=506)Training set (n=531)(n=67)*
POPPY
Study design: Prospective cohort -
salivary progesterone in PTB prediction.
Recruited: Feb 2011 to Jan 2013.
Sites:, C, E, F, G.
Inclusion: 20+0 to 28+6 weeks gestation, 




Study design: Prospective cohort -validation 
of qfFN for PTB prediction.
Recruited: Oct 2010 to May 2014.
Sites:  A, B, C, D, E.
Inclusion:  22+0 to 35+6 weeks gestation, +/-
TPTL; qfFN +/- TVS CL, +/- PTB risk.
Exclusion: PPROM, APH.
(n=444)*
*Some participants were enrolled in more than one study. 
Sites: A=tertiary hospital, Scotland; B=tertiary hospital, London; C=tertiary hospital, London; D=tertiary hospital, London;  E=district general hospital, London, F= district general hospital, North West England; 
G= tertiary hospital, South West England; H=district general hospital, South East England; I=district general hospital, London; J=district general hospital, North East England; K=district general hospital, North 
West England; L=tertiary hospital, North East England; M=district general hospital, North East England; N= tertiary hospital, South West England.
Participants were only included if symptomatic for TPTL and gestation between 23+0 and 34+6; qfFN = quantitative fetal fibronectin; PTB = preterm birth; TPTL = symptoms of threatened preterm labour; 
TVS CL = transvaginal cervical length; PPROM = preterm prelabour ruptured membranes, APH = antepartum haemorrhage; PTB risk =history of spontaneous preterm birth or preterm prelabour ruptured 
membranes, late miscarriage, cervical surgery.  
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Training set (n=1032)  
 With qfFN test (n= 1032 women, 
1173 visits) 




Invalid visit/test results (n=18) 
Sexual intercourse < 24 hours (n=43) 
Major congenital abnormality (n=22) 
Incomplete outcome data (n=42) 
Iatrogenic preterm birth (n=97) 
Participants (n=1760) 
 Pregnant women between 
23+0 and 34+6 weeks’ 
gestation 
 Abdominal pain or tightenings 
suggestive of TPTL 
 
Validation set (n=506) 
 With qfFN test (n= 506 women, 576 
visits) 
 With CL (n= 132 women, 155 visits) 
 With both tests (n= 128 women, 143 
visits) 
 
Final study population (n=1,538) 
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